The Medicines Company To Present New Data On Cardiovascular Portfolio At American Heart Association Scientific Sessions

PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company today announced it will present new data from both its established antithrombotic portfolio and investigational hypercholesterolemia pipeline at the 2015 Scientific Sessions of the American Heart Association, November 7-11 in Orlando, FL.

The presentations at AHA will include a late breaking clinical trial session where new interim findings will be unveiled from the Phase I program on ALN-PCSsc, an RNAi investigational therapy targeting PCSK9 for the treatment of hypercholesterolemia.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC